These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30585294)
21. The apoptotic effect of resveratrol in ovarian cancer cells is associated with downregulation of galectin-3 and stimulating miR-424-3p transcription. El-Kott AF; Shati AA; Ali Al-Kahtani M; Alharbi SA J Food Biochem; 2019 Dec; 43(12):e13072. PubMed ID: 31603261 [TBL] [Abstract][Full Text] [Related]
22. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun. Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707 [TBL] [Abstract][Full Text] [Related]
23. The Tumor Suppressor MicroRNA-1 Exhibits Restricted Inhibition of Proliferation of Ovarian Cancer Cells. Stope MB; Hettenbach D; Kaul A; Paditz M; Diesing K; Burchardt M; Zygmunt M; Mustea A; Koensgen D Anticancer Res; 2016 Jul; 36(7):3329-34. PubMed ID: 27354590 [TBL] [Abstract][Full Text] [Related]
24. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422 [TBL] [Abstract][Full Text] [Related]
25. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409 [TBL] [Abstract][Full Text] [Related]
26. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Guo P; Xiong X; Zhang S; Peng D Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936 [TBL] [Abstract][Full Text] [Related]
27. L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade. Gong J; Xing C; Wang LY; Xie SS; Xiong WD J BUON; 2019; 24(2):701-708. PubMed ID: 31128026 [TBL] [Abstract][Full Text] [Related]
28. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185 [TBL] [Abstract][Full Text] [Related]
29. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Zhang X; Huang L; Zhao Y; Tan W Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606 [TBL] [Abstract][Full Text] [Related]
30. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1. Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988 [TBL] [Abstract][Full Text] [Related]
31. MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. Tian S; Zhang M; Chen X; Liu Y; Lou G Oncotarget; 2016 Dec; 7(52):87091-87099. PubMed ID: 27893429 [TBL] [Abstract][Full Text] [Related]
32. Dysregulation of micro-143-3p and BALBP1 contributes to the pathogenesis of the development of ovarian carcinoma. Zhang H; Li W Oncol Rep; 2016 Dec; 36(6):3605-3610. PubMed ID: 27748916 [TBL] [Abstract][Full Text] [Related]
33. Valspodar-modulated chemotherapy in human ovarian cancer cells SK-OV-3 and MDAH-2774. Zalewski M; Kulbacka J; Saczko J; Drag-Zalesinska M; Choromanska A Bosn J Basic Med Sci; 2019 Aug; 19(3):234-241. PubMed ID: 30957724 [TBL] [Abstract][Full Text] [Related]
34. MicroRNA-509-3p increases the sensitivity of epithelial ovarian cancer cells to cisplatin-induced apoptosis. Chen W; Zeng W; Li X; Xiong W; Zhang M; Huang Y; Zhou L; Jiang S Pharmacogenomics; 2016 Feb; 17(3):187-97. PubMed ID: 26786897 [TBL] [Abstract][Full Text] [Related]
35. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Yan X; Fraser M; Qiu Q; Tsang BK Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436 [TBL] [Abstract][Full Text] [Related]
36. miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells. Bozok Çetintaş V; Tetik Vardarlı A; Düzgün Z; Tezcanlı Kaymaz B; Açıkgöz E; Aktuğ H; Kosova Can B; Gündüz C; Eroğlu Z Tumour Biol; 2016 Feb; 37(2):1739-51. PubMed ID: 26314859 [TBL] [Abstract][Full Text] [Related]
37. MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer. Xiao S; Zhang M; Liu C; Wang D Mol Genet Genomics; 2018 Oct; 293(5):1159-1167. PubMed ID: 29752546 [TBL] [Abstract][Full Text] [Related]
38. A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency. Li N; Chu Y; Yao L; Ying X; Jiang H; Zhou M; Xu C J Cancer Res Clin Oncol; 2011 Oct; 137(10):1455-61. PubMed ID: 21809030 [TBL] [Abstract][Full Text] [Related]
39. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer]. Ma T; Zhang J; Wu J; Tang J Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin. Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]